Poseida Therapeutics (PSTX) Status Update summary

Platform Technology and Pipeline Overview

• Proprietary non-viral genetic engineering tools, including transposon-based gene insertion and Cas-CLOVER editing, enable a robust pipeline in allogeneic CAR-T and in vivo genetic medicines.

• Focus areas include hematology, solid tumors, and autoimmune diseases, leveraging T stem cell memory-rich CAR-T products.

• Booster Molecule technology and selectable marker systems support scalable, high-yield, and consistent manufacturing.

• In-house GMP manufacturing in San Diego/La Jolla enables rapid, cost-effective, and flexible production.

• AI-assisted donor screening and dynamic bioreactor technologies are being explored to further improve efficiency and scale.

Clinical and Preclinical Program Updates

• P-BCMA-ALLO1 for multiple myeloma shows a 91% response rate in phase 1b, including high efficacy in BCMA-experienced patients, with favorable safety and outpatient potential.

• Dual CAR programs (P-CD19CD20-ALLO1, P-BCMA-CD19-ALLO1) target B-cell malignancies and autoimmune diseases, demonstrating robust preclinical and early clinical activity.

• P-CD70-ALLO1 targets AML and RCC, using shRNA knockdown for enhanced potency and safety.

• Solid tumor programs include MUC1C-ALLO1 (phase 1), PSMA-ALLO1 (preclinical), and ConvertibleCAR collaborations with Astellas.

• IND-enabling studies for P-BCMA-CD19-ALLO1 are ongoing, with plans to file INDs for autoimmune indications.

Manufacturing and Operational Excellence

• Fully self-reliant San Diego facility enables rapid, cost-effective, and flexible manufacturing with high-yield, TSCM-rich CAR-T products.

• Rigorous donor screening and selectable marker technology ensure consistent, high-quality starting material and robust manufacturing output.

• Manufacturing process is robust, with donor-dependent but predictable expansion, editing efficiency, and product potency.

• Current capacity allows over 100 doses per donor batch, with plans for further scaling.

• Manufacturing consistency and quality are demonstrated across donor collections, supporting clinical scalability.